ArriVent Advances ARR-217 to Phase 1b Dose Optimization

ArriVent reported initial Phase 1 data for its CDH17-targeted ADC ARR-217 in GI cancers and advanced the program into Phase 1b dose optimization at 5–6 mg/kg every three weeks. Dose optimization data are expected in 2027.